OptiBiotix Health plc SweetBiotix® development: Results of taste study

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announced this morning successful human taste studies in its SweetBiotix(R) product development programme. The programme has been designed to develop sweet natural healthy fibres, called SweetBiotix(R) , which are not digested in the human gut, and hence calorie free.

The study was carried out by The Flavour and Sensory Science Centre at the University of Reading who tested six customised oligosaccharides developed from high intensity sweeteners which were compared to sucrose. The study used a trained expert panel of ten experienced panellists and showed:-

— The customised oligosaccharides showed sweetness of between 140X and 223X that of sucrose at equivalent concentrations

— Customised oligosaccharides derived from Stevia showed a large reduction in bitterness whilst not affecting its sweetness

The results of this independent study provide proof of product concept for a natural, low calorie, SweetBiotix(R). This is an innovative concept which has the potential to address public health concerns over the impact of sugar on obesity, with the prospect of replacing ‘unhealthy’ sugars in existing products with low calorie, healthy non-digestible fibres, trademarked as SweetBiotix(R).

Given the global sweetener market, currently dominated by sugar, is forecast to reach $112bn by 2022 (Mordor Intelligence, 2017), the Company are filing additional patents to add a further layer of protection to the existing intellectual property portfolio to protect their inventions and fully exploit the commercial potential.

Stephen O’Hara, CEO of OptiBiotix, told DirectorsTalk: “We are really pleased with the results of this study which opens up opportunities for the development of a range of natural sweet prebiotic fibres which can be used to replace sugar in food and beverages. These may be classified as dietary fibres, which from an industry and consumer perspective, creates the prospect of substituting high calorie sugars with sweet healthy fibres. With growing public and political concerns over traditional sugars and artificial sweeteners OptiBiotix is leading research in an area of growing industry interest.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really